Journey Medical Corporation (DERM) Dividend History

Company News

• Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

  Journey Medical Corporation announced that the FDA has approved Emrosi™, a new treatment for inflammatory lesions of rosacea in adults. The approval is supported by positive data from the company's Phase 3 clinical trials.

  GlobeNewswire Inc.
• Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

  SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 1:00 p.m. ET.

  GlobeNewswire Inc.

  Featured Companies: FBIO
• Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

  New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024

  GlobeNewswire Inc.

  Featured Companies: FBIO
• Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

  Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET

  GlobeNewswire Inc.

  Featured Companies: FBIO
• Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

  SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company’s Interim Chief Financial Officer since January 2023 and he served as the Company’s Corporate Controller prior to that since November 2021.

  GlobeNewswire Inc.